GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jiangsu Cowin Biotech Co Ltd (SHSE:688426) » Definitions » Debt-to-Equity

Jiangsu Cowin Biotech Co (SHSE:688426) Debt-to-Equity : 0.02 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jiangsu Cowin Biotech Co Debt-to-Equity?

Jiangsu Cowin Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥12.7 Mil. Jiangsu Cowin Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥18.2 Mil. Jiangsu Cowin Biotech Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,630.0 Mil. Jiangsu Cowin Biotech Co's debt to equity for the quarter that ended in Mar. 2024 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Jiangsu Cowin Biotech Co's Debt-to-Equity or its related term are showing as below:

SHSE:688426' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.02   Max: 0.09
Current: 0.02

During the past 6 years, the highest Debt-to-Equity Ratio of Jiangsu Cowin Biotech Co was 0.09. The lowest was 0.01. And the median was 0.02.

SHSE:688426's Debt-to-Equity is ranked better than
87.83% of 1068 companies
in the Biotechnology industry
Industry Median: 0.15 vs SHSE:688426: 0.02

Jiangsu Cowin Biotech Co Debt-to-Equity Historical Data

The historical data trend for Jiangsu Cowin Biotech Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Cowin Biotech Co Debt-to-Equity Chart

Jiangsu Cowin Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.01 0.06 0.07 0.02 0.02

Jiangsu Cowin Biotech Co Quarterly Data
Dec18 Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.02 0.02 0.02

Competitive Comparison of Jiangsu Cowin Biotech Co's Debt-to-Equity

For the Biotechnology subindustry, Jiangsu Cowin Biotech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Cowin Biotech Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jiangsu Cowin Biotech Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Jiangsu Cowin Biotech Co's Debt-to-Equity falls into.



Jiangsu Cowin Biotech Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Jiangsu Cowin Biotech Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Jiangsu Cowin Biotech Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jiangsu Cowin Biotech Co  (SHSE:688426) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Jiangsu Cowin Biotech Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Jiangsu Cowin Biotech Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Cowin Biotech Co (SHSE:688426) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Yaocheng Avenue, 4th Floor, TQB Building, Jiangsu Province, Taizhou, CHN, 225300
Jiangsu Cowin Biotech Co Ltd is a national high-tech enterprise with independent intellectual property rights based in the field of life sciences. It provides innovative biological products and services to in vitro diagnostic users. The product line mainly includes molecular diagnostic raw materials enzymes, nucleic acid collection and protection agents, nucleic acid extraction kits, molecular diagnostic detection reagents and others.
Executives
Yin Jian Feng Director
Zhuang Zhi Hua Directors, senior managers

Jiangsu Cowin Biotech Co (SHSE:688426) Headlines

No Headlines